glp 1 cardioprotective The Cardiovascular Biology of Glucagon-like Peptide-1 Glucagon-like peptide 1 receptor agonists:

Some Medicare patients will be able to access GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more...

Smriti Choudhary, MD, at Primary Care Center of Clear Lake.

In this review we summarize the results of recent cardiovascular outcome trials and discuss the potential clinical advantage of SGLT2 inhibitors and GLP-1 receptor agonists

Tell FDA leaders to put patient safety and evidence-based medicine first before the June 30, 2026 public comment deadline

Pharmaceutical giant Pfizer Inc

Hengrui Pharma and Kailera Therapeutics presented new ADA 2026 data for ribupatide (HRS9531 / KAI-9531), a GLP-1/GIP dual agonist being developed as both a once-weekly injection and a once-daily oral therapy for obesity and overweight